Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.
Kaspar BrochEinar GudeKristjan KarasonGöran DellgrenGöran RådegranGrunde GjesdalFinn GustafssonHans EiskjaerJyri LommiMarkku PentikäinenKarl B LemströmArne K AndreassenLars Lysgaard GullestadPublished in: Clinical transplantation (2020)
The EVOLVD trial is a randomized clinical trial designed to show whether treatment with the PCSK9 inhibitor evolocumab can ameliorate CAV over the first year after heart transplant.